Biocon Ltd - Sep 16, 2024 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
10%+ Owner
Signature
BIOCON LIMITED, By: /s/ Kiran Mazumdar-Shaw, Title: Executive Chairperson
Stock symbol
BCAX
Transactions as of
Sep 16, 2024
Transactions value $
$0
Form type
4
Date filed
9/16/2024, 04:39 PM
Previous filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCAX Common Stock Conversion of derivative security $0 +4.33M +3738.32% $0.00 4.44M Sep 16, 2024 By Biocon Limited F1, F2
transaction BCAX Common Stock Conversion of derivative security $0 +1.08M $0.00 1.08M Sep 16, 2024 By Biocon Pharma Inc. F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security $0 -40M -100% $0.00 0 Sep 16, 2024 Common Stock 4.33M By Biocon Limited F1, F2
transaction BCAX Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security $0 -9.99M -100% $0.00 0 Sep 16, 2024 Common Stock 1.08M By Biocon Pharma Inc. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date.
F2 Shares held by Biocon Limited ("Biocon Ltd"). Kiran Mazumdar-Shaw is the managing member of Biocon Ltd. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3 Shares held by Biocon Pharma Inc. ("Biocon Pharma"). Kiran Mazumdar-Shaw is the managing member of Biocon Pharma. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.